Para Advisors adds Alexion Pharmaceuticals (ALXN) to its portfolio

Alexion Pharmaceuticals (ALXN) : Para Advisors added new position in Alexion Pharmaceuticals during the most recent quarter end. The investment management firm now holds 7,500 shares of Alexion Pharmaceuticals which is valued at $1,000,800 , the company said in a statement filed on Aug 12, 2016 with the SEC.Alexion Pharmaceuticals makes up approximately 10.56% of Para Advisors’s portfolio.

Other Hedge Funds, Including , Hsbc Holdings Plc reduced its stake in ALXN by selling 5,453 shares or 5.13% in the most recent quarter. The Hedge Fund company now holds 100,774 shares of ALXN which is valued at $13,447,283. Alexion Pharmaceuticals makes up approx 0.04% of Hsbc Holdings Plc’s portfolio. Quantres Asset Management Ltd added ALXN to its portfolio by purchasing 11,200 company shares during the most recent quarter which is valued at $1,408,960. Alexion Pharmaceuticals makes up approx 0.84% of Quantres Asset Management Ltd’s portfolio.

Alexion Pharmaceuticals closed down -1.64 points or -1.27% at $127.99 with 9,55,624 shares getting traded on Monday. Post opening the session at $129.59, the shares hit an intraday low of $127.71 and an intraday high of $130.3824 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Alexion Pharmaceuticals reported $1.13 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $1.17. The company had revenue of $753.10 million for the quarter, compared to analysts expectations of $743.05 million. The company’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.

Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Shares were Reiterated by Stifel on Jul 29, 2016 to “Buy” and Lowered the Price Target to $ 182 from a previous price target of $195 .Shares were Reiterated by Barclays on Jul 29, 2016 to “Equal Weight” and Lowered the Price Target to $ 150 from a previous price target of $165 .RBC Capital Mkts Initiated Alexion Pharmaceuticals on Jul 13, 2016 to “Outperform”, Price Target of the shares are set at $188.

Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.

Leave a Reply

Alexion Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Alexion Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.